Hansoh Pharma's Aumolertinib Approved in EU for Lung Cancer Treatment
MT Newswires Live
Feb 20
Hansoh Pharmaceutical (HKG:3692) said its Aumolertinib Mesylate Tablets has been approved in the European Union as monotherapy for certain forms of advanced non-small cell lung cancer, according to a Friday Hong Kong bourse filing.
The approval covers first-line treatment of adult patients with advanced non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as well as treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.